🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

29 results for “Blue” Clear

  1. BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis Delta Infection

    phase 3 small molecule active

    1 trial

  2. BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis Delta Infection

    phase 3 small molecule active

    1 trial

  3. BULEVIRTIDE, BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    1 trial

  4. BULEVIRTIDE, BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    1 trial

  5. Elenestinib

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis

    phase 3 small molecule active

    1 trial

  6. Etrasimod Arginine Blue

    Lacuna Pharma Pty Ltd

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  7. Etrasimod Arginine Blue Placebo, Etrasimod Arginine Blue, Etrasimod Arginine Blue

    Lacuna Pharma Pty Ltd

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  8. Intravenous methylene blue administration

    Hospital Authority, Hong Kong

    Severe Sepsis

    phase 3 small molecule active

    1 trial

  9. MITAPIVAT, MITAPIVAT, "Placebo to Match Mitapivat Tablets, 5 mg and 20 mg, are supplied as film-coated, blue, round tablets for oral administration Placebo to Match Mitapivat Tablets, 50 mg or 100 mg, are supplied as film-coated, blue, oblong tablets for oral administration. Placebo to Match Mitapivat Granules, 1 mg, are supplied as film-coated, white, round granules for oral administration", MITAPIVAT

    Lacuna Pharma Pty Ltd

    Anemia in subjects with sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  10. Placebo tablets, ELENESTINIB, ELENESTINIB, ELENESTINIB, ELENESTINIB

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis and SSM

    phase 3 small molecule active

    1 trial

  11. avapritinib

    Blueprint Medicines (Netherlands) B.V.

    GIST

    phase 3 small molecule completed

    1 trial

  12. AZACITIDINE

    Blueprint Medicines (Netherlands) B.V.

    Advanced Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  13. Avapritinib, Avapritinib, Avapritinib

    Blueprint Medicines (Netherlands) B.V.

    Solid Tumors Dependent on KIT or PDGFRA Signaling

    phase 2 small molecule active

    1 trial

  14. Avapritinib, Avapritinib, Avapritinib Placebo Tablets

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis (ISM)

    phase 2 small molecule active

    1 trial

  15. BFB759, Placebo

    Blue Earth Diagnostics Ireland Ltd

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  16. Lutetium (177Lu) rhPSMA-10.1 injection

    Blue Earth Diagnostics Ireland Ltd

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  17. PF-07915503, PF-07915503, PF-07915503, Etrasimod Arginine Blue, PF-07915503

    Pfizer Australia Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  18. Placebo matching BLU-808, tablet, BLU-808, BLU-808

    Blueprint Medicines (Netherlands) B.V.

    Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  19. Placebo, BFB759

    Blue Earth Diagnostics Ireland Ltd

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  20. [68Ga]BED003 injection

    Blue Earth Diagnostics Ireland Ltd

    Colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

    phase 2 small molecule active

    1 trial

  21. A phase 1 study of FluBHPVE6E7 immunotherapy in patients with HPV16-associated oropharyngeal squamous cell carcinoma

    Blue Earth Diagnostics Ireland Ltd

    Treatment of human papilloma virus (HPV) associated infections and cancers

    phase 1 other active

    1 trial

  22. A study of different dose levels of FluBHPVE6E7 or placebo in women infected with the virus Human Papilloma Type 16 (HPV 16).

    Blue Earth Diagnostics Ireland Ltd

    Treatment of human papilloma virus (HPV) associated infections, precancers and cancers

    phase 1 other active

    1 trial

  23. Etrasimod Arginine Blue

    Pfizer Australia Pty Ltd

    Ulcerative Colitis and immune-mediated inflammatory disorders

    phase 1 small molecule active

    1 trial

  24. Methylene Blue (50 mg/10ml)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Cancer

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources